Exagen Inc. (XGN)

Market Cap	32.75M
Revenue (ttm)	55.73M
Net Income (ttm)	-19.36M
Shares Out	17.37M
EPS (ttm)	-1.09
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	26,605
Open	1.890
Previous Close	1.890
Day's Range	1.831 - 1.933
52-Week Range	1.300 - 3.471
Beta	1.21
Analysts	Buy
Price Target	7.00 (+272.34%)
Earnings Date	May 13, 2024

About XGN

Exagen Inc. develops and commercializes various testing products under the AVISE brand in the United States. The company enables healthcare providers to care for patients through the diagnosis, prognosis, and monitoring of autoimmune and autoimmune-related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). Its lead testing product is AVISE CTD that enables differential diagnosis for patients presenting with symptoms indicative of various connective tissue diseases (CTDs) and other related diseases with overlap...

• Industry: Diagnostics & Research
• Sector: Healthcare
• IPO Date: Sep 19, 2019
• Employees: 174
• Stock Exchange: NASDAQ
• Ticker Symbol: XGN

Financial Performance

In 2023, Exagen's revenue was $52.55 million, an increase of 15.33% compared to the previous year's $45.56 million. Losses were -$23.69 million, -50.01% less than in 2022.

Analyst Forecast

According to one analyst, the rating for XGN stock is "Buy" and the 12-month stock price forecast is $7.0.

Price Target

$7.0

(272.34% upside)

Analyst Consensus: Buy